What is Biocryst Pharmaceuticals Inc worth?
With the base-case assumptions below, a discounted cash flow model on Biocryst Pharmaceuticals Inc's reported free cash flow gives $50.77 per share. The share price was $7.53 on November 10, 2026, 85% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $30.31 | +303% |
| Base | 15.0% | 9.0% | $50.77 | +574% |
| Bull | 20.0% | 8.0% | $88.86 | +1,080% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $66.26 | $71.08 | $76.99 | $84.37 | $93.85 |
| 8.0% | $54.62 | $57.75 | $61.45 | $65.89 | $71.32 |
| 9.0% | $46.15 | $48.30 | $50.77 | $53.65 | $57.06 |
| 10.0% | $39.74 | $41.26 | $42.98 | $44.96 | $47.23 |
| 11.0% | $34.71 | $35.83 | $37.08 | $38.48 | $40.07 |
Where the presets come from
Base: years 1 to 5 grow at Biocryst Pharmaceuticals Inc's revenue growth rate over the last 5 fiscal years (117.9% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions